Tuberculosis incidence in patients with psoriasis who receive anti- TNF- alpha therapies in Latin America: systematic review and meta-analysis
DOI:
https://doi.org/10.15381/anales.v80i1.15623Keywords:
Tuberculosis, Psoriasis, Etanercept, Infliximab, AdalimumabAbstract
The global incidence of tuberculosis in patients with psoriasis who receive anti- tumoral necrosis factor (TNF)- alpha in Latin America remains unknown, despite of the increasing use of those therapies and the local high incidences of tuberculosis, so a systematic review and meta-analysis on the subject was carried out. For that review, there were included studies reporting the tuberculosis incidence in patients with psoriasis receiving anti- TNF- alpha in Latin America, using four electronical databases: Pubmed, Scielo, LILACS and Medigraphic, and then to perform a meta-analysis about those incidences in order to obtain pooled proportions. Finally, 9 studies were selected, which were performed in Argentina, Brasil, Chile, Colombia and México, with a total follow-up of 510,9 patient-years, and with three cases of tuberculosis, giving a pooled incidence of 636 cases of tuberculosis per 100,000 patient-years (95% confidence interval [CI 95%]: 145-1764 per 100,000 patient-years), after using the fixed effects model, which was high according to the stimates of the regional population- based tuberculosis incidence, and similar to other studies performed in patients with psoriasis who receive anti- TNF- alpha in different locations.
Downloads
Published
Issue
Section
License
Copyright (c) 2019 Anales de la Facultad de Medicina
![Creative Commons License](http://i.creativecommons.org/l/by-nc-sa/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Those authors who have publications with this magazine accept the following terms:
- Authors will retain their copyrights and guarantee the journal the right of first publication of their work, which will be simultaneously subject to Creative Commons Attribution License that allows third parties to share the work as long as its author and its first publication this magazine are indicated.
- Authors may adopt other non-exclusive licensing agreements for the distribution of the version of the published work (eg, deposit it in an institutional electronic file or publish it in a monographic volume) provided that the initial publication in this magazine is indicated.
- Authors are allowed and recommended to disseminate their work over the Internet (eg: in institutional telematic archives or on their website) before and during the submission process, which It can produce interesting exchanges and increase quotes from the published work. (See El efecto del acceso abierto ).